Three Broad researchers honored by NIH’s High-Risk, High-Reward Program
Erin Chen and Sam Peng receive the NIH Director's New Innovator Award for innovative, early-career investigators; JT Neal receives the NIH Director's Transformative Research Award for bold, groundbreaking research.
Erin Chen, Sam Peng, and JT Neal (left to right).
Broad Institute core members Erin Chen and Sam Peng have each been awarded the NIH Director’s New Innovator Award, one of the National Institutes of Health’s (NIH) most prestigious awards for early-career researchers.
JT Neal, an institute scientist at the Broad Institute, has been granted an NIH Director’s Transformative Research Award for research that could create or overturn fundamental scientific paradigms. He received the NIH New Innovator Award in 2021.
These awards are part of the NIH’s High-Risk, High-Reward Research Program and support creative, high-impact science and unconventional approaches to challenges in biomedical research. Chen, Peng, and Neal are among 58 researchers who are receiving awards from this program.
Erin Chen joined the Broad in 2023 as a core institute member and is also an assistant professor of biology at MIT and an attending dermatologist at Massachusetts General Hospital. Her New Innovator Award will fund research on how bacteria living on the skin can generate T cell responses that combat disease without causing inflammation. Insights from this work could potentially lead to new immunotherapies.
Sam Peng came to the Broad in 2022 as a core institute member and is an assistant professor of chemistry at MIT. His New Innovator Award will support the development of novel single-molecule microscopy techniques to study the mechanisms of G-protein-coupled receptor (GPCR) signaling pathways. GPCRs mediate the signaling of many hormones and neurotransmitters, and their dysregulation can lead to a range of diseases. This research could contribute to the development of new therapeutics.
JT Neal has been a researcher at the Broad for nearly a decade and is an institute scientist and director of systems genomics, as well as an investigator in the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease at Broad. He has developed technologies for massively parallel functional genomics, single-cell imaging and transcriptomics, and ex vivo modeling for immuno-oncology. He has also led systematic efforts to translate disease-associated genomic variants into actionable therapeutic hypotheses.
His Transformative Research Award will support the creation of Encore, an innovative experimental and computational platform for drug discovery and repurposing for rare genetic diseases. Encore will screen thousands of drugs against hundreds of disease-associated phenotypes simultaneously, testing more than 1.6 million drug-disease combinations with the aim of finding candidate therapies for hundreds of rare diseases in parallel.